Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.

摘要: The HER2/neu oncogene is overexpressed in up to 70% of human pancreatic cancer specimens when compared normal tissue. This cell surface receptor can be targeted specifically by the neutralizing antibody Herceptin. Herceptin has been successfully used combination with other chemotherapeutic agents breast cancer, a which only 30% patients harbor elevated levels. In present study, we investigated therapeutic efficacy gemcitabine and docetaxel. Gemcitabine currently standard agent treat cancer. contrast, docetaxel, taxane, just being Tumor resistance taxanes at least part mediated HER2/NEU oncogene. We have previously characterized expression lines studied anti-tumor activity monotherapy vitro vivo. therapy resulted dramatic improvement animals bearing xenografts. Furthermore, metastasis production ascites was lower these three used. conclude that, as may improved or gemcitabine.